Key Events This Week
Apr 27: Stock dips sharply to Rs.2,039.25 (-3.49%) amid broader market gains
Apr 28: New 52-week high at Rs.2,200 and all-time high at Rs.2,176.05
Apr 29: Minor correction to Rs.2,097.40 (-0.16%) with Sensex recovery
Apr 30: New 52-week and all-time highs at Rs.2,278.85 and Rs.2,235 respectively, closing at Rs.2,230.90 (+6.37%)
Monday, 27 April 2026: Sharp Decline Amid Market Rally
Fredun Pharmaceuticals began the week on a cautious note, closing at Rs.2,039.25, down 3.49% from the previous Friday’s close of Rs.2,112.90. This decline contrasted with the Sensex’s strong 1.14% gain to 35,751.09, indicating stock-specific selling pressure. The volume was relatively low at 8,261 shares, suggesting limited participation in the sell-off. Despite the broader market optimism, the stock’s drop may have reflected profit booking after recent gains or short-term technical adjustments.
Tuesday, 28 April 2026: Breakout to New 52-Week and All-Time Highs
Fredun Pharmaceuticals rebounded sharply on 28 April, surging 3.02% to close at Rs.2,100.85. Intraday, the stock hit a new 52-week high of Rs.2,200 and an all-time high of Rs.2,176.05, marking a significant milestone. This rally was driven by robust financial results and positive market sentiment within the Pharmaceuticals & Biotechnology sector. The stock outperformed the Sensex, which declined 0.28% to 35,650.27, highlighting its relative strength. Volume increased to 10,799 shares, supporting the price advance.
Financially, the company reported a 56.70% increase in net sales to Rs.160.93 crores for the December 2025 quarter, with operating profit nearly doubling (+99.09%). Profit before tax excluding other income rose 96.35% to Rs.14.00 crores, and profit after tax increased 96.6% to Rs.10.48 crores. Promoter stake also rose by 1.11% to 44.17%, signalling strong insider confidence.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
Wednesday, 29 April 2026: Minor Correction Amid Market Recovery
The stock experienced a slight pullback on 29 April, closing at Rs.2,097.40, down 0.16%. This minor correction came despite the Sensex gaining 0.45% to 35,811.60, reflecting a short-term consolidation after the previous day’s strong gains. Volume remained healthy at 9,904 shares, indicating continued investor interest. The stock maintained its position well above key moving averages, preserving its bullish technical setup.
Thursday, 30 April 2026: New Highs and Strong Outperformance
Fredun Pharmaceuticals capped the week with a powerful rally on 30 April, surging 6.37% to close at Rs.2,230.90. The stock reached an intraday 52-week high of Rs.2,278.85 and an all-time high close of Rs.2,235, outperforming the Sensex, which declined 0.83% to 35,515.95. This marked the highest weekly close for the stock in over a year, underscoring strong bullish momentum.
Intraday volatility was elevated at 6%, with the stock fluctuating between Rs.2,021 and Rs.2,278.85. The rally was supported by sustained financial strength, with the company’s operating profit growth of 58.31% annually and a return on capital employed of 20.2%. The PEG ratio of 0.6 suggests the stock remains reasonably valued relative to earnings growth. Promoter confidence remained high, with a 44.17% stakeholding.
Thinking about Fredun Pharmaceuticals Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this micro-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Daily Price Comparison: Fredun Pharmaceuticals vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-04-27 | Rs.2,039.25 | -3.49% | 35,751.09 | +1.14% |
| 2026-04-28 | Rs.2,100.85 | +3.02% | 35,650.27 | -0.28% |
| 2026-04-29 | Rs.2,097.40 | -0.16% | 35,811.60 | +0.45% |
| 2026-04-30 | Rs.2,230.90 | +6.37% | 35,515.95 | -0.83% |
Key Takeaways
Strong Financial Performance: The company’s latest quarterly results showed near doubling of operating profit and profit after tax, with net sales rising over 56%, underpinning the stock’s rally.
Promoter Confidence: An increase in promoter stake to 44.17% signals strong insider belief in the company’s growth prospects.
Technical Momentum: The stock consistently traded above all key moving averages, with bullish MACD, KST, and Bollinger Bands indicators supporting sustained upward momentum.
Market Outperformance: Fredun Pharmaceuticals outperformed the Sensex by over 5% during the week, highlighting its relative strength amid mixed market conditions.
Valuation Metrics: A PEG ratio of 0.6 and ROCE of 20.2% suggest the stock is reasonably valued given its earnings growth and capital efficiency.
Volatility and Corrections: The week saw some volatility, including a sharp drop on Monday and a minor correction midweek, indicating healthy profit-taking and consolidation phases.
Conclusion
Fredun Pharmaceuticals Ltd’s performance during the week ending 30 April 2026 reflects a robust combination of strong financial results, rising promoter confidence, and positive technical signals. The stock’s ability to hit multiple new highs and outperform the broader market amidst volatility underscores its resilience and growth trajectory. While valuation remains reasonable relative to earnings growth, investors should note the stock’s micro-cap status and associated liquidity considerations. Overall, the week’s developments reinforce Fredun Pharmaceuticals’ position as a notable momentum stock within the Pharmaceuticals & Biotechnology sector.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
